Jalili, Pégah http://orcid.org/0000-0002-8098-0154
Bowen, Danae http://orcid.org/0000-0001-8755-8135
Langenbucher, Adam
Park, Shinho http://orcid.org/0000-0002-7399-6318
Aguirre, Kevin http://orcid.org/0000-0001-7119-4234
Corcoran, Ryan B. http://orcid.org/0000-0001-8173-5778
Fleischman, Angela G. http://orcid.org/0000-0002-3701-6079
Lawrence, Michael S. http://orcid.org/0000-0002-1307-459X
Zou, Lee http://orcid.org/0000-0003-3094-1058
Buisson, Rémi http://orcid.org/0000-0002-7196-8209
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA197779, CA212154)
California Breast Cancer Research Program (25IB-0020)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 20 December 2019
Accepted: 26 May 2020
First Online: 12 June 2020
Competing interests
: L.Z. has received research funding from Calico. R.B.C. is a consultant/advisory board member for Amgen, Array Biopharma, Astex Pharmaceuticals, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Elicio, Fog Pharma, Fount Therapeutics, Genentech, Guardant Health, LOXO, Merrimack, N-of-one, Novartis, nRichDx, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Taiho, and Warp Drive Bio; holds equity in Avidity Biosciences, C4 Therapeutics, Fount Therapeutics, nRichDx, and Revolution Medicines; and has received research funding from Asana, AstraZeneca, and Sanofi. P.J., D.B., A.L., S.P., K.A., A.G.F., M.S.L., and R.B. declare no competing interest.